Santarus to Present at May and June Investment Conferences
SAN DIEGO -- May 3, 2013
Santarus, Inc. (NASDAQ:SNTS) today announced that Gerald T. Proehl, president
and chief executive officer, will make presentations at the following
*Bank of America/Merrill Lynch Health Care Conference in Las Vegas on
Thursday, May 16, 2013 at 11:20 a.m. Pacific time (2:20 p.m. Eastern
*Deutsche Bank 38th Annual Health Care Conference in Boston on Thursday,
May 30, 2013 at 8:40 a.m. Eastern time (5:40 a.m. Pacific time), and
*Jefferies Healthcare Conference in New York City presenting on Monday,
June 3, 2013 at 3:00 p.m. Eastern time (12:00 p.m. Pacific time).
Webcasts of these presentations will be available during the event at
www.santarus.com and will be archived and available on the website for 14
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring,
developing and commercializing proprietary products that address the needs of
patients treated by physician specialists. The company's current commercial
efforts are focused on five products. UCERIS^™ ^ (budesonide) extended release
tablets for the induction of remission in patients with active, mild to
moderate ulcerative colitis and ZEGERID^® (omeprazole/sodium bicarbonate) for
the treatment of certain upper gastrointestinal disorders are promoted to
gastroenterologists. GLUMETZA^® (metformin hydrochloride extended release
tablets) and CYCLOSET^® (bromocriptine mesylate) tablets, which are indicated
as adjuncts to diet and exercise to improve glycemic control in adults with
type 2 diabetes, and FENOGLIDE^® (fenofibrate) tablets, which is indicated as
an adjunct to diet to reduce high cholesterol, are promoted to
endocrinologists and other physicians who treat patients with type 2 diabetes.
Full prescribing and safety information for Santarus’ products is available at
Santarus’ product development pipeline includes the investigational drug
RUCONEST^® (recombinant human C1 esterase inhibitor). A biologics license
application (BLA) for RUCONEST was submitted to the FDA in April 2013 for the
treatment of acute angioedema attacks in patients with HAE. Santarus is also
developing rifamycin SV MMX^®, which is in Phase III clinical testing for
treatment of travelers’ diarrhea. In addition, the company has completed a
Phase I clinical program with SAN-300, an investigational monoclonal antibody.
More information about Santarus is available at www.santarus.com.
Santarus cautions you that statements included in this press release that are
not a description of historical facts are forward-looking statements. The
inclusion of forward-looking statements should not be regarded as a
representation by Santarus that any of its plans will be achieved. Actual
results may differ materially from those set forth in this release due to the
risks and uncertainties inherent in Santarus’ business, including, without
limitation: difficulties or delays in development, testing, manufacturing and
marketing of, and obtaining and maintaining regulatory approvals for,
Santarus’ products; and other risks detailed in Santarus’ prior press releases
as well as in public periodic filings with the Securities and Exchange
You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All forward-looking
statements are qualified in their entirety by this cautionary statement and
Santarus undertakes no obligation to revise or update this news release to
reflect events or circumstances after the date hereof. This caution is made
under the safe harbor provisions of Section 21E of the Private Securities
Litigation Reform Act of 1995.
Santarus^®, FENOGLIDE^®, UCERIS^™, and ZEGERID^® are trademarks of Santarus,
Inc. GLUMETZA^® is a trademark of Biovail Laboratories International S.r.l.
licensed exclusively in the United States to Depomed, Inc. CYCLOSET^® is a
trademark of VeroScience LLC. MMX^® is a trademark of Cosmo Technologies
Limited. RUCONEST^® is a trademark of Pharming Group N.V.
Martha L. Hough, VP Finance & Investor Relations
Debra P. Crawford, Chief Financial Officer
Westwicke Partners, LLC
Stefan Loren, Ph.D., 858-356-5930
Robert Uhl, 858-356-5932
Press spacebar to pause and continue. Press esc to stop.